NASDAQ$ALDX
Aldeyra Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Aldeyra Therapeutics reported financial results for Q3 2021 and provided recent corporate highlights.
Aldeyra Therapeutics reported a net loss of $15.8 million for the quarter ended September 30, 2021, compared to a net loss of $8.9 million for the same period in 2020. The company's cash and cash equivalents were $241.4 million as of September 30, 2021, which is projected to fund operating expenses through 2023.
- Top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 trials in dry eye disease are expected in Q4 2021.
- Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa is on track to initiate in Q4 2021.
- Phase 2 clinical trial results of ADX-629 in multiple systemic indications are expected in Q4 2021 or Q1 2022.
- Cash and cash equivalents were $241.4 million as of September 30, 2021, projecting a cash runway through 2023.
Headline financials
Revenue & EPS history
Aldeyra · Revenue · Quarterly
$0
Forward guidance
Aldeyra expects to report top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trials of Reproxalap in Dry Eye Disease in the fourth quarter of 2021, initiate Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa in the fourth quarter of 2021, and expects Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications in the Fourth Quarter of 2021 or the First Quarter of 2022. Company projects cash runway through 2023, including potential New Drug Applications; initial commercialization of Reproxalap, if approved; and continued development of compounds for retinal and systemic diseases.
Tailwinds
- Top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trials of Reproxalap in Dry Eye Disease expected in Q4 2021
- Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in Q4 2021
- Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications Expected in Q4 2021 or Q1 2022
- Cash and cash equivalents expected to be sufficient to fund operating expenses through the end of 2023
- Potential New Drug Application submissions are expected
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.7%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
24 / 51 earnings
Positive
+22.7%
Q4 2026
Best reaction
-14.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +22.7% | -2.3% | -6.4% | |
| Q3 2025 | -2.5% | +10.2% | -2.3% | |
| Q1 2025 | +0.9% | -3.6% | +72.3% | |
| Q4 2024 | +4.5% | +4.4% | -71.5% | |
| Q3 2024 | +2.2% | -11.9% | -3.3% | |
| Q2 2024 | -10.7% | -12.7% | +46.1% | |
| Q1 2024 | -1.0% | -0.7% | -8.1% | |
| Q4 2023 | -7.9% | -23.5% | +20.1% | |
| Q3 2023 | +7.7% | +24.9% | +36.8% | |
| Q2 2023 | +0.8% | -6.6% | -5.0% | |
| Q1 2023 | +3.8% | +0.8% | +4.6% | |
| Q4 2022 | -2.6% | +6.6% | +34.2% | |
| Q3 2022 | +12.2% | +9.5% | +18.5% | |
| Q2 2022 | +15.4% | +24.0% | +11.2% | |
| Q1 2022 | -7.5% | -10.2% | +4.1% | |
| Q4 2021 | +18.4% | +19.4% | +9.1% | |
| Q3 2021 | +10.4% | +6.9% | -6.8% | |
| Q2 2021 | +11.1% | +8.4% | +4.3% | |
| Q1 2021 | +4.3% | +4.8% | +5.6% | |
| Q4 2020 | +3.6% | -3.1% | -0.3% | |
| Q3 2020 | -1.6% | -1.6% | +5.7% | |
| Q2 2020 | -4.4% | -11.4% | -21.6% | |
| Q1 2020 | -2.7% | +14.3% | +64.8% | |
| Q4 2019 | -10.0% | -27.6% | -15.4% | |
| Q3 2019 | -1.7% | +1.0% | -21.6% | |
| Q2 2019 | -4.2% | -0.7% | -9.4% | |
| Q1 2019 | -2.9% | -7.0% | -14.4% | |
| Q4 2018 | +2.3% | +20.2% | +15.1% | |
| Q3 2018 | -13.1% | -11.1% | -6.2% | |
| Q2 2018 | +8.4% | +5.6% | +10.5% | |
| Q1 2018 | +2.9% | +1.7% | +0.0% | |
| Q4 2017 | -14.1% | -14.7% | -1.8% | |
| Q3 2017 | +2.6% | +4.3% | +19.8% | |
| Q2 2017 | -7.4% | -6.4% | -10.6% | |
| Q1 2017 | +7.6% | +12.7% | +17.7% | |
| Q4 2016 | -2.9% | +1.0% | -15.5% | |
| Q3 2016 | +2.7% | -3.6% | -22.5% | |
| Q2 2016 | +0.3% | -2.8% | -3.8% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -3.7% | — | — | |
| Q3 2013 | +5.3% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2013 | +15.0% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q1 2014 | -4.6% | — | — | |
| Q1 2013 | -4.6% | — | — | |
| Q4 2013 | -4.6% | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro